1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Fat Mass and Obesity-associated Protein (FTO)

Fat Mass and Obesity-associated Protein (FTO)

Fat mass and obesity-associated gene (FTO) is a member of the Fe (II)- and oxoglutarate-dependent AlkB dioxygenase family and is linked to both obesity and intellectual disability. Previous studies revealed FTO plays pivotal roles in adipogenesis and energy homeostasis. FTO-deficient mice display postnatal growth retardation and reduced food intake, with a significant reduction of adipose tissue, whereas the overexpression of FTO caused obesity in mice. In addition, the role of FTO as an RNA demethylase of N6-methyladenosine (m6A) may be related to its important roles in neurogenesis, learning and memory. FTO protein is also found to be highly abundant in brain and is associated with reduced brain volume in adolescents and older people. FTO gene deficiency enhances the retention of fear memory and also impairs dopamine receptor 2- and 3-dependent control of neuronal activity and locomotor behavioral responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-137187
    FB23
    98.66%
    FB23 is a potent and selective FTO demethylase inhibitor with an IC50 of 60 nM. FB23 directly binds to FTO and selectively inhibits FTO's mRNA N6-methyladenosine (m6A) demethylase activity.
    FB23
  • HY-B1320
    Meclofenamic acid sodium
    Inhibitor 99.86%
    Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities.
    Meclofenamic acid sodium
  • HY-151106
    FTO-IN-8
    Inhibitor 98.03%
    FTO-IN-8 (FTO-43) is a N6-methyladenosine demethylase (FTO) (fat mass- and obesity-associated protein) inhibitor with the IC50 value of 5.5 μM. FTO-IN-8 has anti-cancer cell proliferative activity.
    FTO-IN-8
  • HY-101082
    N6,2′-O-Dimethyladenosine
    Inhibitor 99.93%
    N6,2′-O-Dimethyladenosine, a substrate of fat mass and obesity-associated gene (FTO), is a reversible modification widely occurred on varied RNA molecules. N6,2′-O-Dimethyladenosine can regulate obesity.
    N6,2′-O-Dimethyladenosine
  • HY-117275
    Meclofenamic acid
    Inhibitor 98.60%
    Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid
  • HY-131871
    Ethyl LipotF
    Inhibitor
    Ethyl LipotF is a selective FTO inhibitor that significant increases modified N6-methyladenosine (m6A) levels in HeLa cells in a concentration-dependent manner.
    Ethyl LipotF
  • HY-145238
    FTO-IN-6
    98.94%
    FTO-IN-6 is a selective fat mass and obesity associated protein (FTO) inhibitor.
    FTO-IN-6
  • HY-149334
    ZLD115
    Inhibitor 99.24%
    ZLD115 (compound 44) is a FB23-derivated inhibitor of Fat Mass and Obesity-associated Protein (FTO). ZLD115 is an antileukemic agent, exhibiting antiproliferative activity against leukemic cell lines.
    ZLD115
  • HY-132865
    FTO-IN-3
    99.79%
    FTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
    FTO-IN-3
  • HY-138843A
    FTO-IN-1 TFA
    98.04%
    FTO-IN-1 TFA is a fat mass and obesity-associated enzyme (FTO) inhibitor extracted from patent WO2018157843A1, compound 32, with an IC50 of <1 μM. FTO-IN-1 TFA can be used for the research of cancer.
    FTO-IN-1 TFA
  • HY-147011
    FTO-IN-7
    Inhibitor 99.22%
    FTO-IN-7 is an inhibitor of FTO. FTO-IN-7 can be used in study Alzheimer's diseases, breast cancers, small-cell lung cancers,a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma.
    FTO-IN-7
  • HY-132863
    FTO-IN-2
    FTO-IN-2 is a FTO inhibitor that impairs self-renewal in glioblastoma stem cells.
    FTO-IN-2
  • HY-139820
    FTO-IN-4
    FTO-IN-4 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).
    FTO-IN-4
  • HY-139821
    FTO-IN-5
    FTO-IN-5 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).
    FTO-IN-5
  • HY-138843
    FTO-IN-1
    FTO-IN-1 is a fat mass and obesity-associated enzyme (FTO) inhibitor extracted from patent WO2018157843A1, compound 32, with an IC50 of <1 μM. FTO-IN-1 can be used for the research of cancer.
    FTO-IN-1
  • HY-156405
    FTO-IN-10
    Inhibitor
    FTO-IN-10 (compound 7) is a potent human demethylase FTO (the fat mass and obesity-associated protein) inhibitor with an IC50 of 4.5 μM. FTO-IN-10 enters the FTO’s structural domain II binding pocket through hydrophobic and hydrogen bonding interactions. FTO-IN-10 induces DNA damage and autophagic cell death in A549 cells.
    FTO-IN-10
  • HY-117275A
    Meclofenamic acid sodium hydrate
    Inhibitor
    Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid sodium hydrate
  • HY-W588293
    3-Methylthymidine
    3-Methylthymidine can be used to detect fat mass and obesity-associated protein (FTO) activity.
    3-Methylthymidine
Cat. No. Product Name / Synonyms Application Reactivity